News
TipRanks on MSN5d
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 studyAtea Pharmaceuticals (AVIR) announced that the first patient has been dosed in C-BEYOND, Atea’s Phase 3 trial evaluating the regimen of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback